维斯科特-阿尔德里奇综合征患者的互白素-1阻塞:一个回顾性的跨国病例系列
Samuele Naviglio1, Maria Pia Cicalese2,3,4, Elizabeth Rivers5
1Institute for Maternal and Child Health IRCCS "Burlo Garofolo," Trieste, Italy.
Blood
|July 24, 2024
概括
抗干白素1 (IL-1) 药物有效治疗威斯科特-阿尔德里希综合征 (WAS) 患者的自身免疫和炎症问题. 这些治疗方法可以迅速缓解症状,并有助于将患者连接到基因疗法或造血干细胞移植 (HSCT).
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 遗传学 遗传学 是一个
背景情况:
- 威斯科特-阿尔德里奇综合征 (WAS) 经常涉及自身免疫和炎症性疾病.
- 介素1 (IL-1) 调节障碍与WAS病变发生有关.
- 在WAS中抗IL-1药物的疗效的证据有限.
研究的目的:
- 评估抗IL-1药物的有效性,以控制WAS的炎症表现.
- 在WAS患者中评估anakinra和canakinumab的安全性和耐受性.
- 确定IL-1阻断作为通往基因疗法或HSCT等最终疗法的桥梁的作用.
主要方法:
- 对9名WAS患者的多中心回顾性分析,这些患者接受了anakinra或canakinumab的治疗.
- 审查患者关于炎症症状,治疗反应和结果的数据.
- 在先前接受过抗IL-1药物治疗的患者中,血液造血干细胞移植 (HSCT) 后的结局分析.
主要成果:
- 所有9名患者都对抗IL-1药物产生了迅速而显著的反应,包括患有严重系统性炎症综合征的患者.
- 抗IL-1疗法促进了基因疗法 (4名患者) 或HSCT (5名患者) 的桥梁.
- 治疗一般耐受良好,HSCT后的低捐赠者髓化合症通过进一步的HSCT或长期的抗IL-1疗法进行管理.
结论:
- 在WAS的炎症表现显著依赖IL-1.
- 用阿纳金拉和卡纳基努马布等药物对IL-1进行药理学阻断是WAS的安全有效的治疗策略.
- 抗IL-1药物为HSCT或基因疗法提供了关键的桥梁,改善了患者的治疗结果.
更多相关视频
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
14.6K
12:36Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
9.4K
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
126
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
126